Lung cancer remains the preeminent cause of cancer mortality worldwide, presenting formidable challenges to modern oncology, particularly in patients harboring epidermal growth factor receptor (EGFR) mutations. Contemporary therapeutic approaches primarily utilize targeted tyrosine kinase inhibitors (TKIs) such as gefitinib and osimertinib, which have significantly improved progression-free survival by effectively inhibiting aberrant EGFR activity. Despite these advances, the relentless emergence of acquired resistance to TKIs continually undermines long-term treatment efficacy, catalyzing the need for deeper molecular insights into the mechanisms driving resistance and disease progression.
A growing body of evidence implicates metabolic reprogramming—especially augmented aerobic glycolysis—as a central hallmark of tumor survival and adaptation under therapeutic stress. However, the complex epigenetic regulatory pathways enabling this metabolic shift and sustaining TKI resistance remain incompletely understood. The recent investigation published in Genes & Diseases introduces a groundbreaking multi-layered epigenetic network centered on the KDM3A/METTL16/PDK1 axis, which orchestrates the metabolic and transcriptional adaptations conferring resistance in EGFR-mutated non-small cell lung cancer (NSCLC).
The study revealed that pyruvate dehydrogenase kinase 1 (PDK1), acting as a gatekeeper of glycolysis by phosphorylating and inactivating pyruvate dehydrogenase, is markedly overexpressed in TKI-resistant lung cancer cells and correlated with poor overall prognosis in patient cohorts. This overexpression drives a metabolic phenotype facilitating glycolytic flux, lactate production, and enhanced cell survival despite TKI treatment. Insightfully, the authors identified a dual regulatory mechanism elevating PDK1 levels: transcriptional derepression mediated by the histone demethylase KDM3A and post-transcriptional stabilization governed by the m6A RNA methyltransferase METTL16.
At the transcriptional level, KDM3A selectively demethylates repressive histone H3 lysine 9 methylation marks (H3K9me1 and H3K9me2) on the PDK1 promoter, thus unlocking chromatin and amplifying transcriptional output. This epigenetic modulation directly potentiates PDK1 mRNA synthesis, reflecting a precise histone modification-dependent control of metabolic enzyme expression. Concurrently, KDM3A upregulates METTL16, an RNA N6-methyladenosine (m6A) methyltransferase, which introduces m6A modifications onto the PDK1 transcript. This m6A signature is subsequently recognized by the reader protein IGF2BP1, which stabilizes the modified mRNA, prolonging its half-life and enhancing PDK1 protein abundance.
This sophisticated coupling of chromatin remodeling and RNA methylation exemplifies an integrative epigenetic axis that fosters metabolic rewiring. The resultant surge in PDK1 levels drives heightened glucose uptake and lactate production, hallmark features of the Warburg effect, thereby fueling the cancer cells’ aggressiveness, proliferative capacity, and resistance to both first- and third-generation EGFR-TKIs. Cellular assays confirmed that depletion of KDM3A, METTL16, or PDK1 re-sensitized resistant NSCLC cells to gefitinib, triggering apoptosis and impeding clonogenic growth, highlighting the pivotal role of this axis in chemoresistance.
Translationally compelling, the investigation extended beyond in vitro findings to validate the therapeutic potential of targeting this pathway in vivo. Using mouse xenograft models implanted with resistant lung cancer cells, combinatorial treatment employing the selective small-molecule PDK1 inhibitor JX06 alongside gefitinib led to a synergistic anti-tumor effect far superior to either agent alone. This drug pairing induced mitochondrial depolarization, increased apoptotic indices as evidenced by flow cytometry, and dramatically curtailed tumor angiogenesis. These outcomes underscore the feasibility of disrupting metabolic-epigenetic crosstalk to overcome drug resistance.
Notably, this study elucidates a previously unrecognized epigenetic-metabolic circuitry propelling TKI resistance and underscores PDK1 as a prime molecular vulnerability. By delineating the concerted action of histone demethylation and mRNA methylation in modulating glycolytic enzyme expression, the research expands therapeutic frontiers beyond conventional kinase inhibition. The synergy between JX06 and gefitinib suggests that precision targeting of metabolic nodes within the resistance network can substantially enhance therapeutic durability.
However, the researchers acknowledge that these promising preclinical results warrant cautious optimism, underscoring the necessity for robust clinical trials to validate efficacy and safety in humans. The complexity and plasticity of tumor epigenomes, alongside interpatient heterogeneity, pose challenges for broad application and underscore the imperative for biomarker-driven patient stratification in future studies. Nonetheless, this work sets a transformative precedent for integrating epigenetic interventions with established targeted therapies.
Collectively, the data position the KDM3A/METTL16/PDK1 axis not only as a mechanistic linchpin of NSCLC TKI resistance but also as an actionable target that could reshape therapeutic paradigms. The dual targeting approach—epigenetic modulation to suppress PDK1 transcriptional activation and pharmacological inhibition of its kinase activity—embodies a sophisticated strategy to dismantle adaptive tumor metabolism while amplifying apoptotic signaling pathways.
This integrative perspective offers new horizons for tackling the intractable issue of acquired resistance in EGFR-mutated lung cancers. As the oncology field increasingly recognizes the pivotal role of epigenomic plasticity and metabolic flexibility in therapeutic escape, studies such as this illuminate potent molecular candidates for next-generation interventions. Implementing tailored regimens combining TKIs with epigenetic and metabolic inhibitors could herald a new era of durable remission and prolonged patient survival.
Future research directing focus toward comprehensive molecular profiling, elucidation of resistance-associated epigenetic signatures, and exploration of combinatory regimen dosing is critical. Understanding potential off-target effects and interactions with tumor microenvironmental factors remains a priority as clinical translation progresses. Moreover, expanding the scope beyond lung cancer to other tumors with similar metabolic dependencies may reveal broader applications of this regulatory axis.
In conclusion, this seminal study establishes the KDM3A/METTL16/PDK1 signaling network as a fundamental driver of metabolic reprogramming and EGFR-TKI resistance in NSCLC. Through sophisticated epigenetic regulation and mRNA modification, cancer cells secure a metabolic advantage that empowers survival under pharmacologic pressure. Targeting this nexus with combined small-molecule inhibitors alongside established TKIs represents a potent strategy with remarkable translational potential, signaling a promising leap forward in the fight against resistant lung cancer.
Subject of Research: Epigenetic and metabolic mechanisms underpinning acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer.
Article Title: PDK1 elevation was induced by epigenetic modifications of KDM3A and METTL16 to mediate TKI resistance and cancer development
Web References:
Journal: Genes & Diseases
DOI: 10.1016/j.gendis.2025.101947
References:
Zhihao Zhou, Ruike Zhang, Zhaoyang Zhang, Liyuan Zhang, Wei Wang, Wenjing Liu, Chunyang Zhang, Gen Lin, Weimiao Yu, Bo Xu, Lin Wang, Bing-Hua Jiang. PDK1 elevation was induced by epigenetic modifications of KDM3A and METTL16 to mediate TKI resistance and cancer development. Genes & Diseases. DOI: 10.1016/j.gendis.2025.101947.
Image Credits: Zhihao Zhou, Ruike Zhang, Zhaoyang Zhang, Liyuan Zhang, Wei Wang, Wenjing Liu, Chunyang Zhang, Gen Lin, Weimiao Yu, Bo Xu, Lin Wang, Bing-Hua Jiang
Keywords: Lung cancer, EGFR-TKI resistance, PDK1, KDM3A, METTL16, epigenetics, m6A methylation, metabolic reprogramming, glycolysis, NSCLC, gefitinib resistance, osimertinib resistance
Tags: aerobic glycolysis and tumor survivalEGFR-mutated non-small cell lung cancerepigenetic regulation of drug resistanceKDM3A METTL16 PDK1 axismetabolic reprogramming in cancermolecular mechanisms of TKI resistanceovercoming acquired resistance to EGFRprognostic biomarkers for lung cancerpyruvate dehydrogenase kinase 1 in cancertargeted tyrosine kinase inhibitorstherapeutic targets for TKI-resistant NSCLCTKI resistance in lung cancer
